Identification and quantification of SARS-CoV-2 leader subgenomic mRNA gene junctions in nasopharyngeal samples shows phasic transcription in animal models of COVID-19 and dysregulation at later time points that can also be identified in humans
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
Introduction
SARS-CoV-2 has a complex strategy for the transcription of viral subgenomic mRNAs (sgmRNAs), which are targets for nucleic acid diagnostics. Each of these sgRNAs has a unique 5’ sequence, the leader-transcriptional regulatory sequence gene junction (leader-TRS-junction), that can be identified using sequencing.
Results
High resolution sequencing has been used to investigate the biology of SARS-CoV-2 and the host response in cell culture models and from clinical samples. LeTRS, a bioinformatics tool, was developed to identify leader-TRS-junctions and be used as a proxy to quantify sgmRNAs for understanding virus biology. This was tested on published datasets and clinical samples from patients and longitudinal samples from animal models with COVID-19.
Discussion
LeTRS identified known leader-TRS-junctions and identified novel species that were common across different species. The data indicated multi-phasic abundance of sgmRNAs in two different animal models, with spikes in sgmRNA abundance reflected in human samples, and therefore has implications for transmission models and nucleic acid-based diagnostics.
Article activity feed
-
SciScore for 10.1101/2021.03.03.433753: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources The LeTRS was also tested with a combined Nanopore cDNA ARTIC v3 amplicon dataset of 7 published viral cell culture samples (barcode01-barcode07) 16, and a dataset from a published direct RNA Nanopore sequencing analysis Vero cells infected with SARS-CoV-2 or an uninfected negative control 2. Verosuggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)Software and Algorithms Sentences Resources The generated raw FastQ files (2 x 250 bp) were … SciScore for 10.1101/2021.03.03.433753: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources The LeTRS was also tested with a combined Nanopore cDNA ARTIC v3 amplicon dataset of 7 published viral cell culture samples (barcode01-barcode07) 16, and a dataset from a published direct RNA Nanopore sequencing analysis Vero cells infected with SARS-CoV-2 or an uninfected negative control 2. Verosuggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)Software and Algorithms Sentences Resources The generated raw FastQ files (2 x 250 bp) were trimmed to remove Illumina adapter sequences using Cutadapt v1.2.1 26. Cutadaptsuggested: (cutadapt, RRID:SCR_011841)The reads were further trimmed to remove low quality bases, using Sickle v1.200 27 with a minimum window quality score of 20. Sicklesuggested: (Sickle, RRID:SCR_006800)The LeTRS was also tested with a combined Nanopore cDNA ARTIC v3 amplicon dataset of 7 published viral cell culture samples (barcode01-barcode07) 16, and a dataset from a published direct RNA Nanopore sequencing analysis Vero cells infected with SARS-CoV-2 or an uninfected negative control 2. SARS-CoV-2suggested: (Active Motif Cat# 91351, RRID:AB_2847848)Sequencing data alignment and basic filtering: LeTRS controlled Hisat2 v2.1.0 28 to map the paired-end Illumina reads against the SARS-CoV-2 reference genome (NC_045512.2) with the default setting, and Minimap2 v2.1 29 to align the Nanopore cDNA reads and direct RNA-seq reads on the viral genome using Minimap2 with “–ax splice” and “-ax splice -uf -k14” parameters, respectively. Minimap2suggested: (Minimap2, RRID:SCR_018550)LeTRS provided 10 known leader-TRS junctions to improve alignment accuracy by using “--known-splicesite-infile” function in Hisat2 and “--junc-bed” function in Minimap2, but this application could be optionally switched off by users. Hisat2suggested: (HISAT2, RRID:SCR_015530)In order to remove low mapping quality and mis-mapped reads before searching the leader-TRS junction sites, LeTRS used Samtools v1.9 30 to have basic filtering for the reads in the output Sam/Bam files according to their alignment states as shown (Table 9 - basic filtering). Samtoolssuggested: (SAMTOOLS, RRID:SCR_002105)Leader-TRS junction plotting: LeTRS-plot was developed as an automatic plotting tool that interfaces with the R package ggplot2 v3.3.3 to view the leader-TRS junctions in the tables generated by LeTRS (Figure 3-5). ggplot2suggested: (ggplot2, RRID:SCR_014601)Results from OddPub: Thank you for sharing your code.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
